Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-08-08
2009-10-20
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S183000
Reexamination Certificate
active
07605160
ABSTRACT:
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB and TrkC thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
REFERENCES:
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 6869952 (2005-03-01), Bhide et al.
patent: 6982265 (2006-01-01), Hunt et al.
patent: 2006/0084650 (2006-04-01), Dong et al.
patent: WO 00/71129 (2000-11-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, vol. 1, 1004-1010, 1996.
Mass, R. D., Int. J. Radiation Oncology Bio. Phys.vol. 58(3): 932-940, 2004.
Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.
Chen Ping
Fink Brian E.
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Korsen Elliott
LandOfFree
Pyrrolotriazine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolotriazine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolotriazine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4141680